Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Conditions
- Platinum-resistant Ovarian Cancer
- Platinum-refractory Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- High-grade Serous Ovarian Cancer
- Endometrioid Ovarian Cancer
- Ovarian Clear Cell Carcinoma
Interventions
- BIOLOGICAL: olvimulogene nanivacirepvec
- DRUG: Platinum chemotherapy: carboplatin (preferred) or cisplatin
- DRUG: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- DRUG: Bevacizumab (or biosimilar)
Sponsor
Genelux Corporation
Collaborators